Wave Life Sciences Ltd. (WVE) AI Stock Analysis

Wave Life Sciences Ltd. is a clinical-stage genetic medicine company focused on designing, optimizing, and producing stereopure oligonucleotides using its proprietary PRISM platform. These molecules target ribonucleic acid to modulate protein expression, reduce disease-promoting proteins, or restore functional proteins. Its development pipeline includes candidates such as WVE-004 for amyotrophic lateral sclerosis and frontotemporal dementia, WVE-003 for Huntington's disease, WVE-N531 for Duchenne muscular dystrophy, and programs targeting spinocerebellar ataxia 3. Wave is also pursuing GalNAc-conjugated AIMers for Alpha-1 antitrypsin deficiency and preclinical programs for retinal diseases, including Usher syndrome type 2A and retinitis pigmentosa.

Revenue has fluctuated significantly over the past five fiscal years, moving from $41.0M in FY2021 down to $3.6M in FY2022, before reaching $113.3M in FY2023 and $108.3M in FY2024. In FY2025, revenue fell 60.5% to $42.7M, and gross margin declined to 79.3% from 100.0% in previous years. Research and development expenses grew to $182.8M in FY2025, leading to an operating margin of -504.1% and a net income of -$204.4M. For the latest quarter ended June 30, 2026, quarterly revenue dropped 73.9% year-over-year, while trailing twelve-month revenue stood at $65.4M with an EPS of -$1.08.

As of June 30, 2026, Wave Life Sciences held $490.6M in cash and short-term investments compared to $43.6M in total debt, resulting in net cash of $447.0M. The company has a current ratio of 9.99 and a debt-to-equity ratio of 0.10 against shareholders' equity of $453.5M. In FY2025, operating cash flow was -$187.5M and capital expenditures were $718,000, yielding free cash flow of -$187.5M. Ongoing financing needs have expanded the equity base, with the share count increasing 253.4% over five years.

Wave Life Sciences carries a market capitalization of $616.8M and an enterprise value of $331.3M. The stock trades at a price-to-sales multiple of 9.4x and an enterprise value-to-revenue ratio of 5.1x, compared to a price-to-sales median of 4.1x for its US-listed Healthcare peer group. Its price-to-book ratio is 1.7x. The company's stock has declined 60.2% over the past year, underperforming the S&P 500 benchmark return of 16.8% over the same timeframe.

Wall Street coverage includes 16 Strong Buy, 2 Buy, and 2 Hold recommendations, with zero Sell or Strong Sell ratings. The mean price target is $17.22, representing an upside of 450.1% over the October 16, 2026 close of $3.13. For the fiscal year ending December 31, 2026, analysts estimate an EPS of -$1.10 on revenue of $50.6M. For the following fiscal year, 18 analysts project revenue to decline 30.4% to $35.2M with an EPS of -$1.17. Wave has beaten EPS estimates in 1 of the last 4 quarters, with next earnings scheduled for November 9, 2026.

This page is an AI-written research summary of Wave Life Sciences Ltd. (WVE). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: WVE income statement, WVE balance sheet, WVE key metrics, WVE analyst forecast, WVE chart. See the WVE stock overview for the latest quote and news.